Short-course Hypofractionated Radiotherapy in Combination With Raltitrexed and Tislelizumab
The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced esophageal squamous cell carcinoma.
Esophageal Squamous Cell Carcinoma
PFS, progression free survival, 1 month post treatment]
ORR, objective response rate, 1 month post treatment]|1ï¼Œ3-year overall survival, Adverse effect, overall survival, Adverse effect, 1 month post treatment]
The goal of this observational study was to explore the safety and efficacy of short course hypofractionated radiotherapy combined with Raltitrexed and Tislelizumab in the treatment of patients with relapsed or advanced esophageal squamous cell carcinoma.